Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response.
about
Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studiesImpact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaSecond-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of lifeA critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorderChanges in body weight and psychotropic drugs: a systematic synthesis of the literatureAccess to credible information on schizophrenia patients' medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers.Schizophrenia: overview and treatment options.Patient perspectives on antipsychotic treatments and their association with clinical outcomes.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Quantitative levels of aripiprazole parent drug and metabolites in urine.Factors affecting treatment discontinuation and treatment outcome in patients with schizophrenia in Korea: 10-year follow-up study.Clinical potential of lurasidone in the management of schizophrenia.Pathways to aggression in schizophrenia affect results of treatmentLong acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory.Effects of Clozapine and other Atypical Antipsychotics on Infants Development Who Were Exposed to as Fetus: A Post-Hoc Analysis.Quantifying clinical relevance in the treatment of schizophrenia.Tecla: a telephone- and text-message based telemedical concept for patients with severe mental health disorders--study protocol for a controlled, randomized, study.Recommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region.Role of aripiprazole in treatment-resistant schizophrenia.Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia.Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics.Postinjection Delirium/Sedation Syndrome with Olanzapine Depot Injection.Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational study.Switching away from pipotiazine palmitate: a naturalistic study.The pharmacological management of violence in schizophrenia: a structured review.New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.Antipsychotic switching in schizoaffective disorder: A systematic review.Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazolePharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.The Use of Long-Acting Injectable Antipsychotics in Schizophrenia.Antipsychotic Management of Schizoaffective Disorder: A Review.Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review.Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With SchizophreniaPaliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder.Leading indicators of community-based violent events among adults with mental illness.A longitudinal analysis of the overlap between violence and victimization among adults with mental illnesses.Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.Long-acting injectable antipsychotics in first-episode schizophrenia.Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia.Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.
P2860
Q24289439-1352B03A-7DA3-4A12-A816-6245F13D9643Q24597701-0E4B6434-8E67-46A8-A609-1AB704E82A40Q26752965-1583DBD3-A5C7-421F-9CA0-07B20F0D81F5Q26766541-8BFE4101-AF6C-4E3A-AB41-656786B1E6CFQ28728401-7D8F989F-5C0C-4AE2-A05A-8C893A26D3FAQ33879034-08B111AF-E334-4AEE-9AE5-A31257961461Q34154951-E08DC572-1235-4F43-8F77-F219B5E5B6D4Q34231565-F6C18ED2-27BF-4676-83D9-2F6597084C36Q34418847-1CC1441D-FE43-4184-99A6-8ABA94D5ED48Q34459567-EFF6092D-C6D4-4E8B-B68D-56693A337340Q34811937-5D9923C9-F17C-4678-86D0-C180B822D4D3Q35093143-A7D3A158-6BB2-437A-8028-20121C13C1D3Q35177162-8B615E65-0647-40E0-B586-B0C965AD9840Q35211261-ACD9D075-8C92-45B7-9AE0-CA7C56B03E7EQ35536187-E0DA53A0-92D8-4B2B-AB1B-6D09D6BE9E6FQ35819467-8E19AD5E-29EE-461B-9030-F6C2E1DB700AQ35832638-1BE44034-5354-4C0B-9250-1014B56747C8Q35984960-DEB91717-3AB6-48A3-A344-397B753C82C8Q36026776-1157A7A2-50F1-4E82-A9FE-196AB0BFBF0BQ36597061-C466CCB9-A7A5-4646-98A2-949D1F55D80AQ36672952-84DBAE76-B1C2-40B7-91E5-361C6C1973D4Q37167256-7FE88257-03F9-4969-9046-13D81197E3C7Q37425737-B652DB5C-D567-403A-909F-DCF5FB4495EFQ37582712-A12F0566-5EB2-4DB3-A816-5F4F5CDF9C31Q37820986-D4545ED0-BA36-450D-B553-897294F22067Q38125213-52C3A5F7-8D8E-4AAD-A334-C1CD080D7FDAQ38370545-0BF69B6C-1075-472C-8EAF-232CBA5FC3A8Q38407027-D6B10EE4-FFAC-443E-A783-0C8E279B8C39Q38734961-7921336A-4276-4D83-A3E4-891F00EE566DQ38744570-74ED0179-87F3-46AF-9FB3-DDC6AD71B59BQ38755501-07AFD675-259C-479E-8764-3041DB337DB2Q38852539-57CFF02E-2FD8-4E78-8D3C-2CD05C0D5C65Q38871120-E0C16D47-69D9-4591-9568-91B44011CE46Q39073819-239B1CAB-3CE1-42F5-9553-1B2E6D169736Q39081911-0E92074A-66B6-46F3-AB06-1150DB40A231Q40411482-223A5A11-D334-46A6-8EC9-E704B77118F7Q40906666-EF29CF35-CF7E-4440-926D-A7C5518A95E6Q41991738-050C7B81-8E4C-4D22-999B-8AE8C437F895Q42131509-99CEBE81-C792-48C4-8A80-4F58E7862692Q42279135-0C061F02-BA88-48CE-8C1E-467613BD27A4
P2860
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Medication nonadherence and tr ...... ith suboptimal prior response.
@en
type
label
Medication nonadherence and tr ...... ith suboptimal prior response.
@en
prefLabel
Medication nonadherence and tr ...... ith suboptimal prior response.
@en
P2093
P356
P1476
Medication nonadherence and tr ...... ith suboptimal prior response.
@en
P2093
Bruce J Kinon
David H Adams
Hong Liu-Seifert
Jan Volavka
Jean-Pierre Lindenmayer
Pandurang M Kulkarni
Peter F Buckley
Sara E Edwards
Virginia Stauffer
P304
P356
10.4088/JCP.08M04221
P577
2009-06-02T00:00:00Z